New combo aims to stop leukemia return in High-Risk patients
NCT ID NCT05361057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether combining venetoclax with either azacytidine or a DA chemotherapy regimen could prevent relapse in acute myeloid leukemia patients who still have detectable cancer cells (MRD positive) after standard treatment. The trial planned to enroll 20 adults in complete remission but with high-risk MRD. Unfortunately, the study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Venetoclax combined with azacytidine or daunorubicin and cytarabine
What this could lead to
If successful, this approach could help prevent leukemia relapse in patients with persistent minimal residual disease who cannot undergo stem cell transplant.
What could go wrong
The trial was terminated early with only 20 participants, so results are limited. The combination drugs have significant side effects like low blood counts and infection risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HBDH
Tianjin, Tianjin Municipality, 300020, China